Prostate Cancer Market Forecast 2032: Clinical Trials, FDA Approval, Therapies, and Companies by DelveInsight | Pfizer, Orion, Epizyme, Nuvation Bio, Zenith Epigenetics, Regeneron Pharmaceuticals, Cardiff Oncology, AstraZeneca, Merck

(Albany, USA) DelveInsight's "Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Prostate Cancer, historical and forecasted epidemiology as well as the Prostate Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Prostate Cancer market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Prostate Cancer market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Prostate Cancer treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Prostate Cancer market.

Request for a Free Sample Report @ https://www.delveinsight.com/report-store/prostate-cancer-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some facts of the Prostate Cancer Market Report are:
• According to DelveInsight, Prostate Cancer market size is expected to grow at a decent CAGR by 2032.
• Leading Prostate Cancer companies working in the market are Pfizer, Orion, Epizyme, Nuvation Bio, Zenith Epigenetics, Regeneron Pharmaceuticals, Cardiff Oncology, AstraZeneca, Merck & Co, Clarity Pharmaceuticals, Laekna Limited, Amgen, Tavanta Therapeutics, Exelixis, Bayer, Matrix Biomed, Janssen Research & Development, LLC, BioXcel Therapeutics, Hinova Pharmaceuticals, Innocrin Pharmaceutical, Janux Therapeutics, POINT Biopharma, Suzhou Kintor Pharmaceuticals, Leap Therapeutics, Jemincare, Immunic AG, Corbus Pharmaceuticals, Advaxis, Inc., Ayala Pharmaceuticals, Bracco Diagnostics, Inc., enGene, HOOKIPA Pharma, CellVax Therapeutics, Fusion Pharmaceuticals, RhoVac, Oncternal Therapeutics, Eli Lilly and Company, Vaccitech, BioNTech SE, Fortis Therapeutics, Inc., Veru Inc., Onxeo S.A, Ambrx, ESSA Pharma, Teneobio, Inc., Bristol-Myers Squibb, Tracon Pharmaceuticals Inc., and others.
• Key Prostate Cancer Therapies expected to launch in the market are HB-300, ZEN 3694, ADXS31-142, Talazoparib, Zilovertamab, BAY2315497, Capivasertib, JMKX002992, LAE001, ADXS-504, Nivolumab, Tarlatamab, ChAdOx1-MVA 5T4, Tazemetostat, RV 001, CRB-701, Cabozantinib, MBM-02, ARX517, TRC253, NUV-868, Onvansertib, VT-464, 64Cu-SAR-bisPSMA, ODM-208, TNB-585, BXCL701, GT0918, FOR46, VERU-111, IMU-935, TAVT-45, Pembrolizumab, EPI-7386, JANX007, LY01005, Abemaciclib, DKN-01, HC-1119, NX-1207, REGN5678, JNJ-78278343, AsiDNA, ZEN 3694, ARV-110, BNT112, and others.
• In Feb 2023, Fusion Pharmaceuticals obtained the investigational new drug application for an ongoing Phase II clinical trial called the "TATCIST" trial. This acquisition was made from RadioMedix, Inc. The trial is assessing the efficacy of 225Ac-PSMA I&T, a small molecule designed to target prostate-specific membrane antigen (PSMA), which is found on prostate cancer cells. After the completion of the acquisition, the alpha-emitting radiopharmaceutical under investigation in the TATCIST trial will be referred to as FPI-2265.
• In Feb 2023, BioXcel Therapeutics, Inc. released comprehensive findings from its Phase IIa study involving BXCL701, an experimental oral immune-boosting agent, in combination with pembrolizumab (KEYTRUDA). The trial focused on patients with metastatic castration-resistant prostate cancer (mCRPC) of the small cell neuroendocrine (SCNC) variant, who had received prior chemotherapy for locally advanced or metastatic prostate cancer. The complete results of the trial will be presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium on February 16, 2023, through a rapid abstract presentation and a poster presentation.

Prostate Cancer Overview
Prostate cancer is a prevalent malignancy that develops in the prostate gland of males. It typically progresses slowly and primarily affects older individuals. Prostate cancer originates from abnormal growth of cells in the prostate, leading to the formation of tumors. Common symptoms include urinary problems, such as frequent urination, weak urine flow, and blood in the urine. Diagnosis involves prostate-specific antigen (PSA) testing, digital rectal examination, and prostate biopsy. Treatment options include surgery, radiation therapy, hormone therapy, chemotherapy, and immunotherapy, depending on the stage and aggressiveness of the cancer. Regular screenings and early detection play a crucial role in managing prostate cancer effectively.

Learn more about Prostate Cancer treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/prostate-cancer-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Prostate Cancer Market
The Prostate Cancer market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Prostate Cancer market trends by analyzing the impact of current Prostate Cancer therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Prostate Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Prostate Cancer market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Prostate Cancer market in 7MM is expected to witness a major change in the study period 2019-2032.

Prostate Cancer Epidemiology
The Prostate Cancer epidemiology section provides insights into the historical and current Prostate Cancer patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Prostate Cancer market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Prostate Cancer Epidemiology @ https://www.delveinsight.com/sample-request/prostate-cancer-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Prostate Cancer Drugs Uptake
This section focuses on the uptake rate of the potential Prostate Cancer drugs recently launched in the Prostate Cancer market or expected to be launched in 2019-2032. The analysis covers the Prostate Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Prostate Cancer Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Prostate Cancer market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Prostate Cancer Pipeline Development Activities
The Prostate Cancer report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Prostate Cancer key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Prostate Cancer pipeline development activities @ https://www.delveinsight.com/sample-request/prostate-cancer-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Prostate Cancer Therapeutics Assessment
Major key companies are working proactively in the Prostate Cancer Therapeutics market to develop novel therapies which will drive the Prostate Cancer treatment markets in the upcoming years are Pfizer, Orion, Epizyme, Nuvation Bio, Zenith Epigenetics, Regeneron Pharmaceuticals, Cardiff Oncology, AstraZeneca, Merck & Co, Clarity Pharmaceuticals, Laekna Limited, Amgen, Tavanta Therapeutics, Exelixis, Bayer, Matrix Biomed, Janssen Research & Development, LLC, BioXcel Therapeutics, Hinova Pharmaceuticals, Innocrin Pharmaceutical, Janux Therapeutics, POINT Biopharma, Suzhou Kintor Pharmaceuticals, Leap Therapeutics, Jemincare, Immunic AG, Corbus Pharmaceuticals, Advaxis, Inc., Ayala Pharmaceuticals, Bracco Diagnostics, Inc., enGene, HOOKIPA Pharma, CellVax Therapeutics, Fusion Pharmaceuticals, RhoVac, Oncternal Therapeutics, Eli Lilly and Company, Vaccitech, BioNTech SE, Fortis Therapeutics, Inc., Veru Inc., Onxeo S.A, Ambrx, ESSA Pharma, Teneobio, Inc., Bristol-Myers Squibb, Tracon Pharmaceuticals Inc., and others.

Learn more about the emerging Prostate Cancer therapies & key companies @ https://www.delveinsight.com/sample-request/prostate-cancer-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Prostate Cancer Report Key Insights
1. Prostate Cancer Patient Population
2. Prostate Cancer Market Size and Trends
3. Key Cross Competition in the Prostate Cancer Market
4. Prostate Cancer Market Dynamics (Key Drivers and Barriers)
5. Prostate Cancer Market Opportunities
6. Prostate Cancer Therapeutic Approaches
7. Prostate Cancer Pipeline Analysis
8. Prostate Cancer Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Prostate Cancer Market

Table of Contents
1. Key Insights
2. Executive Summary
3. Prostate Cancer Competitive Intelligence Analysis
4. Prostate Cancer Market Overview at a Glance
5. Prostate Cancer Disease Background and Overview
6. Prostate Cancer Patient Journey
7. Prostate Cancer Epidemiology and Patient Population
8. Prostate Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Prostate Cancer Unmet Needs
10. Key Endpoints of Prostate Cancer Treatment
11. Prostate Cancer Marketed Products
12. Prostate Cancer Emerging Therapies
13. Prostate Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Prostate Cancer Market Outlook (7 major markets)
16. Prostate Cancer Access and Reimbursement Overview
17. KOL Views on the Prostate Cancer Market
18. Prostate Cancer Market Drivers
19. Prostate Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Get the Detailed TOC of the Prostate Cancer Market report here @ https://www.delveinsight.com/sample-request/prostate-cancer-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Report:
• France Healthcare Outlook Report: https://www.delveinsight.com/report-store/france-healthcare-outlook-report
• Acute Pulmonary Embolism Market: https://www.delveinsight.com/report-store/acute-pulmonary-embolism-market
• Choroidal Neovascularization Market: https://www.delveinsight.com/report-store/choroidal-neovascularization-market
• Chronic Cutaneous Ulcer Market: https://www.delveinsight.com/report-store/chronic-cutaneous-ulcer-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Ankylosing Spondylitis Market: https://www.delveinsight.com/report-store/ankylosing-spondylitis-as-market
• Neuroblastoma Market: https://www.delveinsight.com/report-store/neuroblastoma-market
• Eczema Market: https://www.delveinsight.com/report-store/eczema-market
• Chemotherapy Induced Thrombocytopenia Market: https://www.delveinsight.com/report-store/chemotherapy-induced-thrombocytopenia-market-size
• Ncfb Market: https://www.delveinsight.com/report-store/non-cystic-fibrosis-bronchiectasis-ncfb-epidemiology-forecast
• Pruritus Market: https://www.delveinsight.com/sample-request/cholestatic-pruritus-market
• Achondroplasia Market: https://www.delveinsight.com/report-store/achondroplasia-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Hyperinsulinemic Hypoglycemia Market: https://www.delveinsight.com/report-store/congenital-hyperinsulinism-market
• Alpha Antitrypsin Market: https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market
• Concussions Market Size: https://www.delveinsight.com/report-store/concussions-market
• Stable Angina Market: https://www.delveinsight.com/report-store/angina-angina-pectoris-market
• Allergic Conjunctivitis Market: https://www.delveinsight.com/report-store/allergic-conjunctivitis-market
• Encephalitis Market: https://www.delveinsight.com/report-store/tick-borne-encephalitis-market
• Intrahepatic Cholangiocarcinoma Market: https://www.delveinsight.com/report-store/intrahepatic-cholangiocarcinoma-market
• Acute Coronary Syndrome Market: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market
• Advanced Renal Cell Carcinoma Market: https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market
• Angioedema Market: https://www.delveinsight.com/report-store/angioedema-market
• Anemia Market: https://www.delveinsight.com/report-store/anemia-market
• Foot And Ankle Devices Market: https://www.delveinsight.com/report-store/foot-and-ankle-devices-market
• Giant Papillary Conjunctivitis Market: https://www.delveinsight.com/report-store/giant-papillary-conjunctivitis-market
• Hepatorenal Syndrome Market: https://www.delveinsight.com/report-store/hepatorenal-syndrome-market
• Optic Neuritis Market: https://www.delveinsight.com/report-store/optic-neuritis-market

Contact Us:
Ankit Nigam
info@delveinsight.com
+91-9650213330
Assistant Manager Marketing
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.